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Abstract: Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophre-
nia, bipolar disorders and other psychotic disorders. However, they might cause metabolic syndrome
(MetS) in terms of weight gain, dyslipidemia, type 2 diabetes (T2D), and high blood pressure,
which are responsible for reduced life expectancy and poor adherence. Importantly, there is clear
evidence that early metabolic disturbances can precede weight gain, even if the latter still remains
the hallmark of AAPs use. In fact, AAPs interfere profoundly with glucose and lipid homeostasis
acting mostly on hypothalamus, liver, pancreatic β-cells, adipose tissue, and skeletal muscle. Their ac-
tions on hypothalamic centers via dopamine, serotonin, acetylcholine, and histamine receptors
affect neuropeptides and 5′AMP-activated protein kinase (AMPK) activity, thus producing a supra-
physiological sympathetic outflow augmenting levels of glucagon and hepatic glucose production.
In addition, altered insulin secretion, dyslipidemia, fat deposition in the liver and adipose tissues,
and insulin resistance become aggravating factors for MetS. In clinical practice, among AAPs, olan-
zapine and clozapine are associated with the highest risk of MetS, whereas quetiapine, risperidone,
asenapine and amisulpride cause moderate alterations. The new AAPs such as ziprasidone, lurasi-
done and the partial agonist aripiprazole seem more tolerable on the metabolic profile. However,
these aspects must be considered together with the differences among AAPs in terms of their efficacy,
where clozapine still remains the most effective. Intriguingly, there seems to be a correlation between
AAP’s higher clinical efficacy and increase risk of metabolic alterations. Finally, a multidisciplinary
approach combining psychoeducation and therapeutic drug monitoring (TDM) is proposed as a
first-line strategy to avoid the MetS. In addition, pharmacological treatments are discussed as well.
Keywords: atypical antipsychotics (AAPs); G protein-coupled receptors (GPCRs); metabolic syn-
drome (MetS); weight gain; type 2 diabetes; dyslipidemia; clozapine; olanzapine
1. Introduction
Antipsychotic (AP) medications are associated with relevant metabolic side effects,
where the so-called metabolic syndrome (MetS) can be responsible for poor adherence,
sub-optimal and discontinuation drug use, resulting in relapse and poor clinical outcome.
In fact, about 20–50% of patients suffering from schizophrenia or other psychotic disorders,
in the long-term, may suspend drug usage with a detrimental effect for their prognosis [1].
In addition, MetS, which has an occurrence of about 40% in chronic schizophrenic
patients, has a relevant impact on their general health conditions [1,2]. MetS is defined by
the presence of metabolic abnormalities, such as large waist circumference, dyslipidemia,
fasting hyperglycemia and elevated blood pressure. Schizophrenic patients have higher
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morbidity and mortality compared to the general population, where cardiovascular prob-
lems are the main cause of this decease and the estimated life expectancy drops down by
10–20 years [3]. However, recent data have confirmed that long term use of atypical antipsy-
chotics (AAPs) in the schizophrenic population is associated with decreased hospitalization
and mortality compared to untreated patients, especially with the use of clozapine [4,5].
The relationship between MetS and schizophrenia is complex and multifactorial,
where the use of APs has a major role. Besides drugs side effects, other factors such
as unhealthy lifestyle, reduced physical activity, smoking, improper diet and genetic
predisposition also contribute to metabolic disturbances [6].
APs are generally divided into typical antipsychotics (TAPs) or first-generation APs
and atypical antipsychotics (AAPs) or second-generation APs, based on the evidence that
AAPs rarely induce motor side effects. However, this distinction has been questioned
by many, so a new classification among AAPs was recently proposed by introducing the
concept of spectrum of atypia that begins with risperidone (the least atypical) and ends with
clozapine (the most atypical), which is still the gold standard for the treatment-resistant
schizophrenia [7].
Unfortunately, AAPs higher efficacy on cognition and negative symptoms of schizophre-
nia is outweighed by the frequent occurrence of MetS and weight gain, thereby limiting their
use in clinical practice and compelling clinicians for constant monitoring of patient conditions.
It is quite surprising that these relevant side effects, in particular for AAPs, have been under-
estimated in the past, but now finally clinicians are addressing these concerns while treating
psychotic disorders.
Different meta-analysis have shown that the use of AAPs is associated with the highest
risk of MetS compared with TAPs, with clozapine and olanzapine being the worse [8].
Importantly, type 2 diabetes (T2D) is not strictly correlated with adiposity. In fact, 25% of
patients develop hyperglycemia without gaining weight and this metabolic alteration can
happen in the early period of the treatments and precede weight gain [9]. On the other
hand, it is important to underline, in the long-term, how weight gain induced by AAPs
undoubtedly represents an aggravating factor in the whole metabolic regulation.
The molecular and cellular mechanisms responsible for these metabolic changes are
complex and involve practically all the organs relevant for metabolism, including the
central and peripheral nervous system.
Indeed, AAPs are drugs targeting many receptors and other proteins, and significantly
affect the activities of many hormones and neuromodulators. Different affinities of AAPs
on dopamine, serotonin, muscarinic, adrenergic, histamine receptors and other molecular
targets (e.g., AMPK) are responsible of their diverse clinical profiles. These receptor targets
are well expressed in the hypothalamic centers, pancreas, liver, adipose tissue and skeletal
muscle where they modulate glucose and lipid homeostasis in the whole body [10].
With these premises, this review aims to analyze the occurrence of MetS during the
use of AAPs by trying to understand the responsible mechanisms in order to identify new
potential targets to avoid and/or reduce this undesired effect.
A multidisciplinary approach combining psychoeducation and therapeutic drug mon-
itoring (TDM) is proposed as a first-line strategy. In addition, pharmacological treatments
are discussed as well.
2. A New Classification for AAPs: The Spectrum of Atypia
Since the discovery of clozapine in the 70’s, the concept of AAPs or second-generation
APs was introduced, referring to a new class of medications that were better tolerable,
especially in terms of motor-related side effects. However, in the following years, it emerged
that the benefits of this new class of drugs were somehow overshadowed due to induced
metabolic side effects such as obesity and diabetes. In addition, clinical evidence underlined
the diversity within the class of AAPs in terms of efficacy and motor and endocrine-related
side effects, highlighting how each AAP was unique and therefore the differences among
TAPs and AAPs were questionable [11].
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To reconcile the concept of atypicality and diversity among the class of AAPs, a new
classification for AAPs was recently proposed by introducing the notion of spectrum of
atypia, that ranges from risperidone, the least atypical, to clozapine, the most atypical,
while all the other AAPs fall within the extremes of this spectrum (Figure 1). Notably,
risperidone and amisulpride can lose their atypicality at higher doses [7]. With this
clarification, the concept of atypia is still intact in its essence referring to a category of APs,
which demonstrate reduced motor problems, reduced hyperprolactinemia, and reduced
worsening of apathy and anhedonia along with a better improvement of negative and
cognitive symptoms of schizophrenia. The most effective AAP is still clozapine, which has
unique clinical properties to treat drug-refractory schizophrenia, psychoses associated
with Parkinson’s disease (PD) and tardive dyskinesia. Unfortunately, these advantages
have to be balanced with the increased risk of the AAPs-induced MetS, which is seen less
with TAPs [12].
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Figure 1. The concept of spectrum of atypia was recently introduced to classify atypical antipsychotics (AAPs). They can be
divided in three categories, where risperidone is least atypical (Level I) and clozapine is most atypical (Level III), while all
others fall within these two extremes of the spectrum (Level II). The molecular targets shown on the right add up, beginning
with the D2 and 5-HT2A,C receptors that are common targets for all AAPs, extending to additional mechanisms such as M1
positive allosterism and GlyT (glycine transporter) activity that seem specific to clozapine. Other targets, such as H1 and α2
receptors and BDNF, are relevant to both Level II and III of atypia [7].
In fact, in clinical practice, many doctors make decisions for a tailored therapy accord-
ing to the patient’s characteristics, drug efficacy and risks of drug-related side effects. As a
consequence, the choice among the different APs is often made by trying to avoid the risk
of motor-related side effects or metabolic abnormalities.
Regarding the mechanism of action, AAPs are weak D2 receptor blockers and they
act beyond D2 antagonism, involving other receptor targets (e.g., serotonin (5-HT) recep-
tors) [13–16]. The ratio of 5-HT2A/D2 and 5-HT2C/D2 receptor affinity together with a
rapid dissociation constant (Koff) from the D2 receptor are two important factors that
distinguish AAPs in terms of efficacy and side effects [17,18]. In addition, other molecular
targets characterize the receptor profile of the ideal AAP, and among them, 5-HT1 partial
agonism, H1 antagonism, α2 antagonism, muscarinic antagonism and positive alloster-
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ism, brain-derived neurotrophic factor (BDNF) production, and glycine transporter (GlyT)
blocking are relevant for AAP’s action. Clozapine has a unique receptor profile on these
molecular targets and therefore it is still considered the gold standard, especially for
treatment-resistant schizophrenia. Recently, new concepts such as biased agonism and
receptor dimerization have been introduced to explain the differences among different
APs [19–21]. It has been found that some AAPs have biased signaling activities at D2
and 5-HT2A receptors, allowing them to preferentially block or activate specific receptor-
mediated intracellular signaling pathways. For instance, clozapine has been shown to act
as a biased agonist in vivo and in vitro at 5-HT2A receptor and to activate ERK and Akt
kinases, and this can be another factor determining clozapine singularity [19,22].
3. Role of GPCRs in the Metabolism of Peripheral Tissues
Glucose and lipid metabolism relies on the coordination between several organs,
including pancreatic β-cells, liver, adipose tissue, and skeletal muscle. In addition, the cen-
tral nervous system (CNS), through the hypothalamic centers via the autonomic nervous
system and the neuroendocrine system, constantly regulates their activity.
Besides insulin and glucagon, the main protagonists for energetic homeostasis, other mod-
ulators determine a fine regulation of the metabolism by mostly acting on the G protein-couled
receptors (GPCRs) that are targeted by AAPs.
For this reason, we briefly summarize the relevance of several GPCRs involved in
the metabolism of peripheral tissues, such as glucagon (GCG) receptors, glucagon-like
peptide-1 (GLP-1) receptors, gastric inhibitory polypeptide (GIP) receptors, muscarinic re-
ceptors, free fatty acid (FFA) receptors, adrenergic receptors, dopamine receptors, serotonin
receptors, and ghrelin receptors.
3.1. GPCRs and Pancreatic β-Cells
Many GPCRs expressed in the pancreatic β-cells are involved in the regulation of
pancreatic islet’s function, and therefore they are potential targets responsible for AAPs-
induced side effects (Figure 2).
The endogenous agonists for GLP-1 receptors are the incretin hormones released by
the intestinal system post-meal ingestion, which enhance the glucose-stimulated insulin
secretion (GSIS) by β-cells [23]. The GLP-1 receptor increases GSIS by activating the Gs
protein and consequently increasing cAMP. In addition, GLP-1 activates Akt and increases
the expression of PDX1 thus causing a cytoprotective and proliferative effect. The GIP
receptor has similar characteristics to GLP-1 and is coupled to Gs protein, which induces
an increase in cAMP and insulin secretion [24].
On β-cells physiology, the Gs-coupled glucagon receptor is important for regulating
insulin secretion, and it seems to have a permissive effect, which guarantees a minimum
concentration of intracellular cAMP necessary for the β-cells activity. Indeed, in pancre-
atic islets isolated from glucagon receptor knockout (KO) Gcgr(−/−) mice, the insulin
responses to glucose and several insulin secretagogues were found to be significantly
reduced when compared with wild-type mice [24,25].
The most expressed muscarinic receptor subtype is the M3, coupled to Gq protein.
Studies in mice have clearly shown that it is involved in the correct maintenance of glucose
homeostasis [26]. Several studies have shown that an increase in parasympathetic activity
can increase insulin secretion during the first minutes of food ingestion [27].
Similar to M3, the FFA receptor GPR40, highly expressed in β-cells, is coupled to Gq
protein and it enhances insulin secretion by increasing intracellular Ca2+ concentration.
It may also effect cell vitality through the activation of the intracellular signaling pathways
of ERK, PI3K and Akt [28]. The other FFA receptor GPR119 expressed in β-cells is associ-
ated with a Gs protein, and it increases insulin secretion by rising the intracellular levels
of cAMP [24].
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the periphery, the liver, pancreatic - ll , ti and skeletal muscle are implicated in APs-induced MetS.
By interfering with the activity of different GPCRs expressed in these regions, AAPs significantly alter glucose and
lipid homeostasis.
Regarding adrenergic recepto s, the two catecholamines, noradrenalin and adrenaline,
inhibit insulin secretion via α2 receptors coupled to Gi protein; however, th pres nce of
β2-adrenergic receptor in the β-cell might indicate its possible ole in insulin secretion
under cert in conditions. In animal mo els, selective KO st dies have shown that the α2A
and α2C subtypes mediate the inhibition of insulin secretion by catecho amines [24].
While the role of sympathetic and parasympathetic systems h s been clearly demon-
strated in β-c ll physiolog , an intriguing activity of peripheral dop m ne nd serotonin
on β-cells has also emerged over the last two decades [29].
In murine species, the expression of the five dopamine receptors in islets and β-cell
cultures, such as INS-1 and MIN6, has been determined using RT-PCR [30]. In particular,
the most expressed subtypes are D2 (long and short) and D3. A subtle inhibitory paracrine
and autocrine function on β-cells has been postulated for local dopamine sourced from
dietary precursors (e.g., L-DOPA) and/or noradrenergic fibers [31–33]. In fact, rodent and
human islets express enzymes such as tyrosine hydroxylase (TH), L-aromatic amino acid
decarboxylase (AADC), vesicular monoamine transporter 2 (VMAT2) and dopamine active
transporter (DAT) to produce and store dopamine [31].
Recently, it was proved that both the D2 and D3 receptors are relevant for inhibiting
GSIS that occurs after the L-DOPA treatment. While the D2/3 agonist quinpirole induced a
dose-dependent inhibition of GSIS, the D2/3 antagonist raclopride was able to block the
inhibitory action of L-DOPA and thus restore the normal levels of insulin [34].
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In relation to serotonin receptors, different subtypes have been detected in β-cells
across different species. However, among them, 5-HT1A/1D/1F, 5-HT2A and 5-HT3 seem
most relevant as their expression may change in response to the metabolic condition [35].
Similar to dopamine, serotonin released mostly by intrapancreatic nerves originated
from the enteric nervous system and/or co-released with insulin by β-cells can influ-
ence insulin secretion [36,37]. In fact, β-cells express tryptophan hydroxylase (TPH) [38]
and AADC, the two enzymes required for serotonin synthesis. Additionally, similar to
dopamine, serotonin can be stored in insulin vesicles via VMAT2 and it can be reuptaken
by serotonin transporter (SERT) [37].
Intriguingly, the role of serotonin in insulin secretion is still not clear because both
in vitro and in vivo studies have found different and contradicting results. It seems that
the administration of serotonin can either reduce or increase GSIS based on expression
of different serotonin receptor subtypes [37]. In β-cell cultures, such as MIN6 and INS-1,
the 5-HT2 selective agonists reduced GSIS whereas in vivo they produced an opposite
effect [39].
3.2. GPCRs and Liver
The liver is the main source of glucose production, and glucagon and insulin constantly
regulate its activity as a consequence of plasma nutrients levels. Besides, other GPCRs also
influence its metabolic activity (Figure 2).
Glucagon receptors cause an increased expression of cAMP, PKA, and CREB, with con-
sequent activation of gluconeogenesis, glycogenolysis and inhibition of glycolysis. In addi-
tion, the cAMP-PKA-CREB pathway also provides a strong stimulus for the turnover of
amino acids in the liver by activating enzymes of the urea cycle [40]. In the liver, the pres-
ence of incretin receptors such as GLP-1 or GIP do not seem significant, whereas ghrelin
receptors are capable of influencing hepatic lipid metabolism by increasing lipogenesis [41].
The sympathetic and parasympathetic activity on liver metabolism is complex and
still controversial. The β2 receptors expressed in hepatocytes influence carbohydrate and
lipid metabolism, and these receptors seem to prevent the accumulation of lipids in mice
receiving fat diet, therefore they are a plausible target for treating fatty liver disease [42].
In fact, genetic deletion of β2 adrenergic receptor aggravates hepatic lipid accumulation and
it has been hypothesized that the lack of β2 alters CREB-mediated regulation of peroxisome
proliferator-activated receptor PPARγ activity in the liver [43].
Regarding muscarinic receptors, acetylcholine alters the hepatic energy metabolism
by stimulating glycogen synthesis, apparently through the Gq-coupled M3 receptor [44].
Similar to β2, the M3 can reduce hepatic lipid accumulation via AMPK activation [45].
Recently, it was suggested that muscarinic receptors are not relevant for maintaining
glucose homeostasis as, surprisingly no significant metabolic differences were found in M3
mutant mice compared to control group, and in addition, the expression of key genes for
regulation of liver metabolism remained unaltered [46]. On this topic, it was proposed that
other GPCRs coupled to Gq protein, such as vasopressin V1b receptor, can be relevant to
regulate hepatic glucose production.
Another GPCR family expressed in hepatocytes are serotonin receptors, namely
5-HT2A/2B and 5-HT3. Activation of the 5-HT2A/2B promotes gluconeogenesis and inhibits
the absorption of glucose, thereby increasing blood sugar during fasting periods [47,48].
Serotonin promotes a similar activity through 5-HT3. In addition, serotonin regulates the
hepatic accumulation of triglycerides via mTOR pathway [49].
3.3. GPCRs and Adipose Tissues
The presence of GIP receptor has been demonstrated in the adipose tissue, while GLP-
1 receptor does not appear to be relevant [50]. Several studies have shown that GIP plays
a role in the metabolism of adipose tissue by increasing the entry of FFA into adipocytes
with a consequent reduction in their plasma levels (Figure 2). In animal studies, GIP is able
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to increase the activity of lipogenesis and lipoprotein lipase. In addition, the possible role
of GIP as a pro-inflammatory factor in adipose tissue has also been considered [51].
Stimulation of the FFA receptor GPR120 activates lipogenesis, which helps to maintain
lipid homeostasis and reduce insulin resistance. GPR120 is coupled to Gq protein and
it induces an increase in intracellular calcium concentration and ERK phosphorylation,
both relevant for stimulating adipogenesis [52].
Lipid metabolism in adipocytes is also influenced by β-adrenergic receptors that
induce lipolysis by increasing cAMP levels and consequently activating the PKA pathway;
on the contrary, insulin counteracts lipolysis and promotes lipogenesis by activating the
Akt pathway. However, despite producing this opposite effect, insulin and catecholamines
seem to converge in some common denominators, such as Akt activation. Interestingly,
insulin resistance and T2D do not alter the hormonal control of lipolysis and the release of
FFA [53].
In the white adipose tissue, serotonin, by stimulating 5-HT2A/2B receptors, promotes
adipogenesis and absorption of lipids from the bloodstream while simultaneously it inhibits
lipolysis induced by β-adrenergic receptors. Whereas in brown adipose tissue, serotonin
reduces cellular activity and energy expenditure [47].
Finally, ghrelin causes an increase in the mass of white adipose tissue via a GHS1
receptor-dependent mechanism that activates intracellular mTOR-PPAR signaling pathway,
and furthermore, the elimination of GHS receptor reduces the absorption of lipids and
lipogenesis [41].
3.4. GPCRs and Skeletal Muscle
The GLP-1 receptor seems to have an unusual activity in muscle tissues, such as
increasing the synthesis of glycogen and the absorption of glucose in an action similar to
insulin [54], and this effect does not involve cAMP but instead the second messenger inosi-
tolphosphoglycan (IPG). Conversely, glucagon receptors, expressed at low concentrations
in the skeletal muscle might reduce absorption of glucose [55] (Figure 2). The exposure
of skeletal muscle to catecholamines induces a slight increase in lipolysis in obese sub-
jects; however, this does not seem to happen in lean subjects, probably due to a different
composition of muscle fibers and their sensitivity to β2-adrenergic receptors [56]. Both cat-
echolamines and serotonin, through Gs protein-coupled receptors, increase cAMP levels
and cause glycogen depletion in rat muscle cells [57].
Histaminergic H1 receptors have an important role in regulating glycogen synthesis
in muscle tissues. Their stimulation activates some key proteins for intracellular signaling
of the insulin receptor, including insulin receptor substrates IRS1/2, and Akt, thereby
inhibiting GSK3 and increasing glycogen synthesis. Furthermore, the H1 receptors also
influence the AMPK pathway, and this could increase the membrane translocation of
glucose transporter type 4 (GLUT-4) [58].
On this topic, the 5-HT2A receptor also appears capable of increasing the absorption
of glucose in the muscle by inducing greater expression of the transported GLUT-4. In fact,
the 5-HT2A antagonists inhibit muscle uptake of glucose [59].
4. Effects of AAPs on Hypothalamus and Peripheral Tissues
The AAPs-induced MetS is the consequence of a very complex and broad activity of
these drugs on the CNS and peripheral organs, especially by interfering with the activity
of GPCRs expressed in these tissues. In addition, if we consider how the CNS through
hypothalamus deeply regulates the peripheral organs by altering the concentrations of
neuromodulators and hormones in the blood system, the role of the CNS and each organ in
the genesis of the AAPs-induced MetS becomes difficult to establish. Therefore, in order to
understand the mechanism of MetS, especially in terms of hyperglycemia and dyslipidemia,
it is desirable to analyze separately the contribution of the hypothalamus and each relevant
organ targeted by AAPs.
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4.1. AAPs and Hypothalamus
Hypothalamus is the main sensor of the nutrient concentrations in the blood, such as
glucose, and it strongly intervenes by influencing glucose and lipid metabolism. Hypotha-
lamus controls glucose and lipid homeostasis coordinating several organs such as the
liver, pancreas, adipose tissue, and skeletal muscle, via the autonomic nervous system
and the neuroendocrine system. Sympathetic stimulation increases noradrenaline and
adrenaline levels, glucagon secretion, production of glucose and lipolysis, and it reduces
insulin secretion leading to transitory blood glucose increase. Conversely, parasympathetic
activation causes the opposite i.e., increases insulin secretion and inhibits production of
glucose [60].
AAPs strongly interfere with hypothalamic centers activity by targeting monoaminer-
gic GPCRs, thus altering descending and ascending autonomic system control. Monoamin-
ergic neurons in the basal brain secrete dopamine, serotonin, noradrenaline and histamine
influencing hypothalamic arcuate (ARC) and paraventricular nuclei (PVN) through the
GPCRs expressed in these areas.
Among the GPCRs targeted by AAPs, antagonism at H1 receptor has been implicated
in hyperphagia, weight gain and metabolic dysregulation [61]. Importantly, H1 seems
relevant in controlling glucose and lipid homeostasis independent of weight gain (Figure 2).
A significant association has been found between the genetic variants of H1 (rs346074-
rs346070) and obesity [62].
A confirmation of the implication of H1 in the mechanism of AAPs comes from
the observation that AAPs with high affinity for this receptor, such as clozapine and
olanzapine, are the strongest for inducing weight gain and metabolic alterations. However,
H1 antagonism is not the only mechanism involved in the hypothalamus because AAPs
have a greater effect on MetS compared to selective antihistaminergic drugs [63]. In fact,
dopaminergic and serotonergic antagonism of AAPs have a great impact on specific
hypothalamic ARC neurons.
It is known that dopamine is relevant for food intake by regulating α-MSH and orexin
expression, therefore D2 antagonism can cause an increase of hunger and thus weight
gain. The ARC nucleus has a high concentration of D2 and D3 receptors [64], and their
blockade can contribute to the deregulation of glucose and lipid metabolism. In addi-
tion, D2 antagonism induces hyperprolactinemia with consequences in food regulation
and metabolism.
Regarding the role of serotonin in the hypothalamic centers, serotonergic neurons
project to the pro-opiomelanocortin (POMC) centers of the ARC nucleus that express
5-HT2A/2C receptors, which reduce the appetite by increasing α-MSH secretion from POMC
neurons that leads to melanocortin 4 receptors (MC4Rs) activation [65,66]. ARC nucleus is
a relevant sensor for energetic homeostasis because it is sensitive to various neuro-humoral
stimuli such as leptin, orexin, insulin, GLP-1, cholecystokinin and ghrelin [63].
Clozapine and olanzapine are potent 5-HT2A/2C antagonists and this is relevant
for their effect on glucose and lipid metabolism, and weight gain [67]. In animal models,
administration of selective 5-HT2A/2C antagonists resulted in significant increases in insulin
resistance and insulin secretion in response to glucose stimulation. Conversely, 5-HT2C
agonists have been proposed for the treatment of hyperglycemia and weight gain, and they
have been experimented in clinical practice [68].
Alterations in hypothalamic orexigenic and anorexigenic neuropeptides expression and
function, including neuropeptide Y (NPY), agouti-related protein (AgRP) and melanocortins
have also been demonstrated during AAPs treatment, mainly due to their interference with
monoaminergic systems.
In several experiments, it has been shown that AAPs, particularly clozapine and
olanzapine, reduce the expression of the anorexigenic peptide POMC and conversely
increase the expression of the orexigenic peptide AgRP and NPY [69].
As a consequence of these remarkable changes in the hypothalamus, AAPs increase
the sympathetic outflow in the periphery by increasing glucagon secretion [70]. Enhanced
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levels of norepinephrine have been found in schizophrenic patients taking clozapine and
risperidone, but not haloperidol [71]. As a confirmation of implication of the sympathetic
system activation, the use of α2 or β-adrenergic receptor antagonist with clozapine was
able to reverse hyperglycemia and reduce insulin secretion caused by clozapine [72].
Another important target whose function is altered during AAPs use is hypothalamic
AMPK. AMPK, highly expressed in the ARC and ventromedial hypothalamus, is a key
player in the regulation of energy homeostasis and metabolism, which is influenced by sev-
eral neurotransmitters and neuropeptides through receptors that are targeted by AAPs [73].
When glucose levels decrease in the brain, AMPK is activated to replenish these levels that
are essential for neuronal activity. Consequently, AMPK activates hepatic gluconeogenesis
and glycogenolysis via stimulation of the sympathetic nervous system, which increases the
secretion of hormones, such as glucagon, corticosterone and epinephrine [74]. AMPK activ-
ity is regulated by nutrients, anorexigenic (e.g., leptin) and orexigenic signals, and AAPs
hinder these sensing mechanisms.
AAPs are known to increase hypothalamic AMPK activity mostly as antagonists at
H1 receptors. In fact, AAPs with high affinity for H1, such as clozapine and olanzapine,
are the strongest AMPK activators, whereas others, such as ziprasidone or lurasidone,
have a minimal effect [75]. A study confirmed this hypothesis where clozapine was unable
to activate hypothalamic AMPK phosphorylation in H1 KO mice, and thus its effect on
food intake or weight gain disappeared in these mice [75]. On this line of evidence,
the histaminergic stimulant betahistine partially reversed the changes in hypothalamic
AMPK activation and NPY expression caused by olanzapine [73].
It should be noted that while AMPK activation in the hypothalamus increases glucose
levels and alters lipid metabolism, the same mechanism has an opposite effect in the
peripheral organs, such as the liver where it lowers glucose production and increases fatty
acid oxidation.
4.2. AAPs and Liver
The liver is the principal location of glucose production, and it has a central role in
the regulation of systemic glucose and lipid fluxes during feeding and fasting. Since the
pancreatic veins drain directly into the portal venous system, every hormone secreted by
the pancreas, such as insulin and glucagon, pass through the liver before entering into the
systemic circulation. About 70% of hepatic glucose output takes place via glycogenolysis
and the remaining 30% via gluconeogenesis [76].
The AAPs-induced increase of glucagon targets the liver that is the principal source
of glucose production, and this excessive production is responsible for the development
of T2D, even at early stages (Figure 2). In fact, clozapine and olanzapine may induce an
increase in glucagon levels even when peripheral glucose levels are high [77]. Glucagon
increases the expression of glucose 6-phosphatase (G6Pase) and phosphoenolpyruvate
carboxykinase (PEPCK) in the hepatocytes [78], which determine the rate of hepatic glu-
cose production.
A confirmation of AAPs-induced glucagon increase for the hyperglycemic effect is
based on early data where olanzapine-induced increase of blood glucose levels was found
abolished in glucagon receptor KO mice [79]. Besides glucagon increase, the diabetogenic
effect induced by AAPs such as clozapine and olanzapine is also mediated by hepatic
insulin resistance as demonstrated in preclinical and clinical studies [80], which contributes
to an abnormal increase of hepatic glucose output [77,81]. This effect was however not
observed with risperidone [81]. The hepatic insulin resistance induced by clozapine can
indeed occur rapidly following a single dose as demonstrated in healthy animals [72].
In relation to hepatic metabolism, AMPK is known to be a key player for glucose home-
ostasis because its activation lowers blood glucose levels, mostly by inhibiting gluconeoge-
nesis. AAPs significantly decrease AMPK activity thereby altering glucose metabolism [82].
In addition, since activated AMPK also regulates the lipid metabolism by inhibiting lipoge-
nesis and increasing fatty acid oxidation, it is reasonable to assume that AAPs increase hep-
Pharmaceuticals 2021, 14, 238 10 of 26
atic lipogenesis through AMPK inhibition, which contributes to liver fat accumulation [83].
AMPK activation inhibits mTORc1 function, therefore AAPs indirectly stimulate mTOR
signaling that increases the expression of the transcriptional activation of sterol-regulatory
element-binding proteins SREBP-1c [83]. SREBPs play a central role in controlling a variety
of lipid biosynthetic pathways, regulating genes for lipid and cholesterol biosynthesis.
AAPs-induced hepatic overexpression of SREBP-1c is relevant for lipid accumulation and
liver steatosis. These adverse effects have been demonstrated for clozapine, olanzapine,
and risperidone, while aripiprazole or haloperidol did not induce the same effect [84].
SREBPs activity appears to be controlled by the downstream pathways of different
receptors present in the liver, and among them, 5-HT2 and H1 have received particu-
lar attention, whose expression is increased in the liver of patients chronically exposed
to AAPs [83,85].
In addition, it has been demonstrated that AAPs decrease the transcriptional activity
of PPAR, another critical regulator of lipolysis and fatty acid oxidation in the liver but also
in the adipose tissue [83].
Pharmacological treatments with antidiabetic drugs such as metformin and PPAR
agonists reduce hepatic steatosis and glucose production through activation of AMPK and
inhibition of SREBP elements, acting opposite to the mechanism of AAPs.
4.3. AAPs and Pancreatic β-Cells
AAPs treatment is associated with T2D, an undesired effect independent of weight
gain. Considering that hyperglycemia and peripheral insulin resistance are common side
effects induced by AAPs, a compensatory hyperinsulinemia should be expected regardless,
and this makes difficult to establish the direct or indirect effects of AAPs on insulin secre-
tion by the pancreatic β-cells. In fact, determining the effect of AAPs on β-cells activity is
challenging because conflicting results have been reported. Few in vitro studies demon-
strated that clozapine and olanzapine increase basal insulin secretion whereas haloperidol,
ziprasidone or aripiprazole did not induce the same effect [86]. In one study, clozapine
quickly increased basal insulin secretion at high concentrations; however, it did not alter
glucose-stimulated insulin activity [87]. In vitro early studies proposed an inhibitory effect
induced by some APs on GSIS [88].
These changes were later confirmed in clinical practice where 30–60% of patients using
clozapine or olanzapine showed hyperinsulinemia; however, it is not clear whether this
was a compensatory mechanism to insulin resistance or a direct consequence of β-cells
stimulation by AAPs [87]. Besides, chronic hyperinsulinemia becomes an aggravating
factor for β-cells deterioration and for early onset of T2D.
In relation to the mechanism of AAPs-induced hyperinsulinemia, D2, D3, 5-HT2A/2C
and 5-HT1A receptors expressed in the β-cells might be partially responsible, considering
that peripheral dopamine and serotonin generally inhibit insulin secretion in a subtle
way (Figure 2). In fact, D2 antagonists, such as AAPs and TAPs, slightly increase insulin
secretion, while dopamine agonists have an opposite effect [30]. Dopamine seems to
be produced in the β-cells starting from its precursors present in the diet and/or from
noradrenergic fibers, and in addition, it has a paracrine and autocrine inhibitory function
on insulin secretion via D2 and D3 receptors [30].
Similarly, studies conducted on animal models demonstrated that serotonergic ag-
onists and antagonists have an opposite effects on β-cells insulin secretion by acting on
different serotonergic receptors such as 5-HT2A, 5-HT2C, and 5-HT1 [36].
Therefore, it is plausible that the combination of dopaminergic and serotonergic antag-
onism might contribute to AAPs-induced insulin hypersecretion, more than compounds
that are selective at just one receptor subtype. Additionally, the antimuscarinic properties
of some AAPs, such as clozapine and olanzapine, have an impact on the parasympathetic
control of β-cells insulin secretion. On this aspect, the effect of AAPs is controversial be-
cause besides blocking muscarinic receptors, clozapine and olanzapine seem to increase the
parasympathetic cholinergic output that probably leads to a rebound on the vagal system
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with compensatory stimulation of the β-cells [63,89]. In a study, olanzapine administrated
for 9 days increased insulin and C peptide secretion that was reduced by atropine treatment,
thus confirming the role of muscarinic receptor stimulation [90]. Clozapine and olanzapine-
induced insulin dysregulation may also be partly due to blockade of hypothalamic M3
receptors [91].
Besides, the antagonism of clozapine at α2 receptors expressed on β-cells could reduce
the inhibitory effect of the sympathetic system on insulin secretion, and thus have a role
in hyperinsulinemia.
To demonstrate the difficulty in establishing definitive evidence on AAPs effect on
β-cells insulin secretion, a recent in vitro study found that olanzapine actually reduces
insulin secretion in the nanomolar concentration, whereas other works were conducted
mostly at higher concentrations. The study proposed that blockade of D3, 5-HT2B, 5-HT2C
and H1 receptors expressed in β-cells could be the mechanism responsible for AAPs-
reduced insulin secretion [92].
In conclusion, the effect of AAPs on β-cells insulin secretion is still controversial
and the hyperinsulinemia caused by AAPs as reported by several papers could be due to
peripheral insulin resistance and/or β-cells overstimulation.
4.4. AAPs and Adipose Tissue
Data from animal and human studies have confirmed an increase of lipogenesis, visceral
fat reserves, FFA circulation and differentiation of pre-adipocytes during AAPs treatment [93].
Studies on cultured cells have shown enhanced lipogenesis in rat adipocytes treated with
olanzapine and clozapine [94]. In vivo and in vitro studies both have suggested that clozapine
and olanzapine may increase lipogenesis through SREBP1c up-regulation [95], a transcription
factor for several genes that are implicated in lipid metabolism (Figure 2).
Undesired changes in adiposity and insulin sensitivity were observed after 12 weeks of
AAPs treatment in young patients, including greatest fat increase with olanzapine. In fact,
several trials have shown that this phenomenon is more relevant in patients treated with
olanzapine and clozapine compared to other AAPs [96,97].
In addition, AAPs differ from other drugs because they are capable of inducing
hypertriglyceridemia. Generally, clozapine and olanzapine have the highest propensity to
increase triglycerides levels, while quetiapine and risperidone are associated with moderate
risk, whereas ziprasidone, lurasidone and aripiprazole seem to have a minimal risk [98].
Besides these effects, AAPs such as olanzapine and clozapine also increase plasma
FFAs levels in patients and healthy persons. It is known that increased FFAs impair the
ability of insulin to suppress hepatic glucose production and stimulate glucose uptake by
skeletal muscle [99].
FFAs are generally sequestered from the plasma by hepatocytes, myocytes and
adipocytes and then transformed into activated fatty acids, which are subsequently me-
tabolized via oxidation or conserved via lipogenesis. When FFAs production exceeds the
capacity of these two pathways to dispose them, then FFAs and their intermediates have a
negative effect on insulin action at the cellular level. Some studies have illustrated that an
excess of FFAs induces insulin receptor inactivation and degradation, including disruption
of IRS1 [100,101].
Besides metabolic alterations, it has been demonstrated that AAPs are able to stimulate
the differentiation of preadipocytes into adipocytes, thereby contributing to adipose tissue
mass. In fact, olanzapine and clozapine were found to upregulate the expression of
transcription factors essential for adipocyte differentiation [102]. Due to increased adiposity,
a rise in leptin levels generally occurs, which in the long term can lead to leptin-resistance
in the hypothalamic centers, thereby altering appetite regulation [103]. Recently, it was
shown in 140 subjects that low adiponectin and high leptin levels in dysfunctional adipose
tissues may contribute to increased oxidative stress and inflammation, which can be a
marker for severity of MS [104].
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All these above-mentioned alterations indicate the relevance of adipose tissue in the
onset of MetS that causes insulin resistance, overstimulation of β-cells insulin secretion
and inflammation, which in the long-term could lead to T2D and obesity.
4.5. AAPs and Skeletal Muscle
Based on the evidence that the H1 and 5-HT2A receptors play an important role
in glycogen synthesis and glucose uptake mostly through GLUT-4 in muscle cells, it is
reasonable to expect that glucose metabolism might be locally impacted by AAPs having
strong antagonism at H1 and 5-HT2A, especially by reducing plasma glucose clearance that
contributes to the onset of T2D [59] (Figure 2).
In an in vitro study, olanzapine inhibited IRS-1 and Akt phosphorylation induced by
insulin and impaired insulin-signaling cascade, and this can be relevant for the peripheral
insulin resistance [105]. Similar evidence was also found for clozapine in L6 muscle cells;
however, ex vivo studies on rat-isolated skeletal muscle found contradictive results for
AAPs [59].
Another factor that reduces skeletal muscle sensitivity to insulin is the increase of
plasma FFA. As aforesaid for the adipose tissue, FFA can also interfere negatively with
insulin receptor downstream signaling in the muscle cell and induce receptor degradation
as well [101].
In addition, lipidomic studies on lipid contents (e.g., FFA, phosphatidylcholines and
ceramides) in skeletal muscle biopsies from patients treated with AAPs have found several
differences compared to the general population with potential consequences in insulin
resistance; conversely, mood stabilizers did not cause the same shift [106].
5. AAPs and MetS in Clinical Practice
AAPs are generally considered well-tolerated especially in terms of motor side effects;
however, they often cause MetS, which is responsible for reduced life expectancy and poor
adherence to the therapy. Importantly, there is clear evidence that early metabolic changes
can precede weight gain, an aspect that needs to be properly monitored [9].
Several reviews and meta-analysis that systematically compared AAPs with TAPs
in terms of efficacy and side effects found data supporting AAPs superiority for several
aspects, but with an increased risk of developing MetS [8,107].
However, in terms of MetS, AAPs are a heterogeneous class of drugs. In fact, olanzapine
and clozapine are associated with the greatest risk, whereas quetiapine, risperidone, asenapine,
and amisulpride show a moderate level of this undesired effect (Table 1). Interestingly, ziprasi-
done and lurasidone seem more tolerable on the metabolic profile; however, these drugs are
relatively new thus their therapeutic efficacy in comparison with other AAPs still needs to be
determined. A reduced level of MetS has also been found for aripiprazole, an AAP with a
different receptors profile compared to the other drugs [8,98]. The prevalence of clozapine and
olanzapine-induced MetS is the highest compared to the other AAPs, and it has been reported
to be between 25% to 50% [108,109]. In addition, AAPs polypharmacy is generally associated
with the increasing risk of MetS [110].
TAPs have a lower tendency to produce MetS compared to AAPs, but they might still
induce it, indicating that the D2 receptor blockade has consequences on the metabolism.
Some authors suggested that haloperidol might lead to weight gain and metabolic distur-
bances due to its activity on hypothalamic centers and also to hyperprolactinemia [111].
Surprisingly, the METEOR study (Evaluation of Metabolic disorders in Schizophrenic
patients) in 2006, conducted an analysis to evaluate the differences between TAPs and
AAPs for inducing MetS and it found more similarities than expected, in contrast with
many other meta-analyses, such as the CATIE (Clinical Antipsychotic Trials of Intervention
Effectiveness) study, where the difference was clear. Therefore, even if this study can
be downsized, it still warns about the risk of metabolic alterations associated to the use
of TAPs [95].
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Table 1. Clinical differences between AAPs in terms of negative/cognitive symptoms improvement, MetS (gain, T2D,
dyslipidemia) and parkinsonism. Based on reviews and meta-analysis studies [8,107], values are reported as very high
(++++), high (+++), moderate (++), low (+), very rare (+/−), and with no effect (0).
AAPs Negative/CognitiveSymptoms Improvement Weight Gain Diabetes (T2D) Dyslipidemia Parkinsonism
Clozapine ++++ +++ +++ +++ 0
Olanzapine +++ +++ +++ +++ +/−
Quetiapine ++ ++ ++ ++ +/−
Risperidone ++ ++ ++ ++ ++
Amisulpride ++ ++ ++ ++ ++
Asenapine ++ + + + +
Lurasidone ++ + + + +
Ziprasidone ++ + + + +
Aripiprazole ++ + + + +
In relation to weight gain, several meta-analysis studies have consistently shown
that clozapine and olanzapine are associated with the highest risk, followed in order by
quetiapine, risperidone, paliperidone, and asenapine, whereas the other AAPs, such as
ziprasidone, lurasidone and aripiprazole seem less detrimental on this effect [107].
In the first CATIE study, olanzapine showed a weight gain of almost 1 kg/month, and a
similar conclusion was reached in a following trial over one-year in which olanzapine and
clozapine induced a weight gain of approximately 12 kg while quetiapine and risperidone
increased weight of 2–3 kg [112]. Aripiprazole and asenapine showed relatively little
weight gain where apparently ziprasidone did not show any gain [113,114].
In another study, Fountaine et al. (2010) showed in healthy volunteers how olanzapine
treatment increased the calories intake of 345 kcal per day and the resulting weight gain
of 2.6 kg after 2 weeks. A similar pattern was found in olanzapine-treated schizophrenic
adolescents for 4 weeks, confirming the AAP-induced increase of appetite and excess
caloric intake coupled with increased water retention [115].
Besides causing weight gain, another undesired effect caused by AAPs treatment is
fasting hyperglycemia, which can develop in T2D. Most importantly, this side effect is not
strictly dependent on weight gain, and 25% of the cases of T2D involve people that are not
obese [116]. In fact, the development of hyperglycemia and insulin resistance can happen
in the early period of AAPs treatments (within 6 months) and precede weight gain. Besides,
in the long-term, weight gain undoubtedly becomes an aggravating factor for T2D.
A meta-analysis on 270,000 subjects found that clozapine and olanzapine are associated
with an increased risk of T2D, while risperidone or quetiapine show a moderate risk.
T2D prevalence with the use of AAPs has been shown to range from 3% to 28% [117].
Seven out of nine studies showed a significant association between olanzapine and
T2D, whereas three out of four studies found the same evidence for clozapine [118,119].
Risperidone (five out of nine) and quetiapine (three out of six) also showed a positive
association with T2D, but to a less degree. Evidence for aripiprazole was discordant
probably indicating a lack of clear association [119]. Other AAPs such as ziprasidone,
lurasidone, and asenapine are associated with low risk of T2D. Another study indicated
that the risk of olanzapine-induced T2D was dose-related, while quetiapine and risperidone
showed increased risk only at high doses [120]. Although T2D seems rare in AAP-treated
adolescences, there is evidence of a potential risk based on the duration of the treatment
and on the use of polytherapy [121].
When obesity develops during AAPs use, insulin sensitive tissues become more
resistant to insulin and β-cells increase insulin secretion in order to compensate, which in
the long term can determine β-cells deterioration thus increasing the risk of T2D.
AAPs treatment is also associated with dyslipidemia with rates between 15–50%.
Saari et al. studied a cohort of 5654 patients in Northern Finland and found that the
risk of dyslipidemia in individuals treated with AAPs was increased by 2.8 times for
hypercholesterolemia, 2.3 times for hypertriglyceridemia and 1.6 times for high LDL
cholesterol, and this increase was associated with weight gain [122]. A systematic review
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comparing metabolic effects in different AAPs found that olanzapine and clozapine have
the highest risks for increased cholesterol in addition to weight gain [119]. Another
study found that olanzapine caused the highest cholesterol elevation and increased waist
circumference among different AAPs [109]. Despite the relevance of dyslipidemia and
hyperglycemia in schizophrenic patients, most of them are not treated pharmacologically.
For example, Mackin et al. found that only 7% of patients were receiving lipid-lowering
therapy [123]. In addition, a high percentage of schizophrenic patients had cardiovascular
problems [124].
When any of the above-mentioned metabolic abnormality occurs in patients, evidence
from clinical trials suggests that switching AAP medication from one with high risk of
MetS to another with lesser risk potential could be a potential way to manage these side
effects, but the data are still limited so further examinations are required [125].
Though we focused our analysis on the most used AAPs, one should note that the
more recent ones, such as cariprazine, brexpiprazole, and lumateperone [126], have shown
a lower impact on metabolic parameters (BMI, weight change, LDL levels) when compared
to clozapine or olanzapine [98]. Regarding the mechanism of action of these new AAPs,
we suggest to refer recent reviews by Torrisi et al. and Caraci et al. [127,128].
6. Treatments for AAPs-Induced MetS: Pharmacological and
Non-Pharmacological Interventions
6.1. Non-Pharmacological Interventions
The importance of an intervention aimed at decreasing the risk of AAPs-induced MetS
is crucial considering how it can have a significant impact on patient’s health conditions
and compliance, especially in the long term. In fact, sedentary lifestyle and high-caloric
diet, in association with the use of AAPs, can be detrimental for weight gain, T2D and
dyslipidemia. In addition, weight gain increases the social stigma associated with mental
illness, and it often pushes the patients to abandon their pharmacological therapy.
The first-line treatment for AAPs-induced MetS is based on psychoeducation, physical
exercise and diet. Many studies have underlined how different strategies based on psychoe-
ducation, psychotherapy and health programs can succeed in preventing and/or reducing
the onset of AAPs-induced MetS [129].
A meta-analysis of 17 trials related to psychoeducational, cognitive-behavioral, nutri-
tional and physical activity interventions collected evidence on the effectiveness of health
promotion programs for weight loss and prevention of weight gain in psychotic patients.
The analysis found a substantial and relevant decrease of more than 3% of the initial weight;
besides, the guidelines of the Occupational Medical Service (OMS) and National Institute
of Health (NIH) indicate a weight loss of 5–10% as the optimal criterion for success [130].
On this topic, as a “lifestyle therapy,” the NIH has provided a practical guidance based
on correct diet, increased physical activity and behavioral therapy. The behavioral strate-
gies are focused on improvement of the executive functions, problem-solving skills and
anti-stress techniques to be carried out for at least 6 months.
Scientific literature shows various intervention programs starting from simple com-
mercial manuals to structured psychological therapies, differing in terms of modality,
duration and number of sessions [129].
For example, a study based on the Weight Watchers program, which combines a
regulated diet and motivational psychology, demonstrated weight reduction by 2.3 kg in
patients taking olanzapine compared to 0.2 kg in control group [131].
Furthermore, Barton et al. have pointed out that each therapy should be tailored
to patient-specific characteristics, particularly considering the severity of the symptoms,
and adopt an approach that encourages small and feasible daily changes such as eliminating
sugary drinks and adding 2000 steps each day [129,132]. Similar evidence emerges from a
case-controlled study conducted on 70 patients treated with olanzapine, where a healthy
intervention program seems to be effective in maintaining body weight up to 4 months [133].
Other educational strategies that were successful in preventing or reducing weight gain
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include a multidisciplinary approach based on strong motivational support (e.g., to have a
diary to record food intake and exercise) and changing incorrect food habits [134,135].
In addition, besides weight control, psychoeducation can be important for trying to
make patients aware of their conditions and on the side effects of the pharmacological treat-
ments to help improve patient’s adherence. On this topic, there are also even more struc-
tured treatments such as cognitive behavioral therapy (CBT) techniques. Weber et al. (2006)
examined the positive results achieved through a group cognitive-behavioral interven-
tion (1 h per week for sixteen weeks) in a diabetes prevention project on patients tak-
ing AAPs [136].
Most psychological interventions focus on change of dysfunctional beliefs and cog-
nitive bias towards unhealthy food habits, and on improvement of emotional states and
sensations related to hunger and satiety, thus promoting healthy behaviors in relation
to food. In addition, other approaches such as role-playing, problem-solving exercises,
motivational encouragement, and the use of diary to record food activities and exercise,
all might contribute to control weight gain and MetS.
6.2. Pharmacological Interventions
When diet or any non-pharmacological intervention tried as first-line treatment is
unable to reduce the AAP-induced MetS, it often becomes necessary to introduce an
appropriate pharmacological therapy. It is quite surprising to notice that a large num-
bers of patients with psychotic disorders having MetS are not pharmacologically treated
with AAPs [137].
In this direction, metformin appears to be one of the most effective drugs to counter
weight gain and T2D induced by AAPs (Table 2). Metformin belongs to the biguanide
family, and it is the main drug used for treating T2D and MetS. By activating AMPK in
the liver and other tissues, metformin reduces hepatic glucose production and lipogen-
esis, stimulates fatty acid oxidation, and facilitates glucose uptake from the blood [138].
Jesus et al. have showed that metformin reduces weight gain and improves insulin sensi-
tivity as well [139]. In a recent review, metformin was shown to be effective on weight gain
and insulin resistance in four out of five studies performed in patients taking AAPs with
metabolic adverse reactions [95].
Table 2. Clinical studies evaluating pharmacological interventions against AAPs-induced MetS.
Added Treatment AAP Study Pharmacological Response Reference
Metformin
Olanzapine
Double-blind study: 25 patients randomly
assigned to olanzapine plus metformin or
olanzapine plus placebo for 24 weeks.
Metformin-group gained 3% of body weight
compared to 7% for placebo group. BMI change was
0.85 in metformin-group vs. 2.02 in placebo-group.
[140]
40 patients randomly assigned treatment
with olanzapine plus metformin or
olanzapine plus placebo for 12 weeks.
Metformin-group vs. placebo group resulted in
lower increase in body weight (1.90 vs. 6.87), fasting
insulin level (0.81 vs. 6.78) and insulin resistance
index (0.22 vs. 1.49).
[141]
80 patients taking olanzapine were
randomized metformin or placebo
comedication treatment for 12 weeks.
Body weight change was −1.4 in metformin-group
and non-significant in placebo. Insulin resistance
increased after placebo and not after metformin.
[142]
40 patients taking olanzapine were assigned
to metformin or placebo for 14 weeks.
No significant improvements for
treated vs. placebo group. [143]
Clozapine
55 subjects taking clozapine for at least
3 months, were assigned to metformin or
placebo for 24 weeks.
Body weight, BMI, fasting plasma glucose, HDL,
insulin level had significant changes in the
metformin-group.
[144]
61 patients treated with clozapine were
randomly assigned to metformin extended
release or placebo for 14 weeks.
Mean change in body weight was −1.87 kg for
metformin-group and 0.16 kg for placebo-group





12-week double blind study on 30 patients
treated with olanzapine were allocated to
rosiglitazione or placebo.
Insulin and the insulin resistance significantly
decreased after rosiglitazone, while no effect was
seen on weight gain and lipid profile.
[146]
Clozapine
8-week double blind, placebo-controlled
trial of rosiglitazone 4 mg/day in
18 clozapine-treated schizophrenia subjects
with insulin resistance.
Non-significant improvement on glucose utilization
and insulin sensitivity index; significant reduction in
LDL level in rosiglitazone group.
[147]
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Table 2. Cont.
Added Treatment AAP Study Pharmacological Response Reference
Liraglutide Olanzapine orclozapine
103 patients with a BMI > 27 and
prediabetes randomly assigned to
liraglutide or placebo for 16 weeks.
Liraglutide-group (63.8%) developed normal glucose
tolerance compared with placebo-group (16%).
Liraglutide induced a placebo-subtracted body
weight loss of 5.3 kg.
[148]
Exenatide Clozapine
28 patients treated with clozapine randomly
assigned to exenatide extended release or
standard care for 24 weeks.
6 people on exenatide achieved >5% weight loss vs.
1 usual care. Participants on exenatide had greater
weight loss (−5.29 kg vs. −1.12 kg), BMI reduction
(−1.78 vs. −0.39), reduced fasting glucose
(−0.34 vs. 0.39) and HbA1c (−0.21 vs. 0.03)
compared to control.
[149]
A study on adult rats treated with olanzapine tested the efficacy of different class of
antidiabetic drugs in combination. Co-administration of metformin with glibenclamide,
or with rosiglitazone or with glibenclamide, reduced glucose levels more than the single
treatments, efficiently counteracting the hyperglycemic effect of olanzapine [150].
The addictive effects of the two drugs can be explained by their complementary action,
since glibenclamide acts on the pancreatic β-cells whereas metformin and rosiglitazone
regulate mostly the metabolism in the liver and in the adipose tissues, respectively [91].
According to these authors, the increase in insulin levels alone is not sufficient to cause
a reduction in hyperglycemia caused by AAPs, as the involvement of other mechanisms
seem relevant. In addition, metformin seems to counter some of the AAPs effects in the
hypothalamic centers. In fact, when prolonged treatment with olanzapine results in an
increase in hypothalamic phosphorylation of AMPK, metformin reduces AMPK activity
with consequences in the food intake and glucose homeostasis [151].
Intriguingly, oral administration of metformin also increased postprandial GLP-1
levels in diabetic patients, which seems to contribute to metformin’s glucose-lowering
effect through AMPK-dependent effect on GLP-1–secreting intestine L cells. In addition,
metformin seems to have cytoprotective properties by stimulating proliferation of pancre-
atic β-cells and reducing cellular apoptosis [152]. In 2006, GLP-1 analogues (lixisenatide,
liraglutide and dulaglutide) were approved for T2D and, at higher doses, they also re-
duce weight [153].
Lykkegaard et al. (2008) conducted an experiment on female rats treated with olanzap-
ine for 14 days followed by GLP-1 analogue liraglutide. Liraglutide succeeded in reversing
the weight gain caused by olanzapine, reduced food intake, normalized glucose tolerance
and demolished mesenteric and retroperitoneal fat stores in rats [154]. A case report of a
schizophrenic woman with T2D triggered by clozapine when treated for 3 months with
liraglutide demonstrated a loss of weight of 6 kg and the glycated hemoglobin value was
stabilized at 6.1% [155].
Considering that AAPs increase hunger, a potential pharmacological strategy is to
try drugs that decrease appetite. One option is reboxetine, a selective norepinephrine
reuptake inhibitor. The increase of norepinephrine can be effective in weight reduction
by reducing appetite [156]. A double-blind placebo-controlled study evaluated the ability
of reboxetine to prevent or mitigate weight gain caused by olanzapine. Results showed
that the control group treated with olanzapine and placebo gained an average of 5.5 kg in
6 weeks, while the group treated with olanzapine and reboxetine only gained an average
of 2.5 kg [157].
On this topic, the use of the selective serotonin reuptake inhibitor (SSRI) fluoxetine is
controversial, as clear evidence was not demonstrated, besides small improvements that
appeared were transient [158].
On olanzapine-induced weight gain, amantadine was found to be effective in losing
an average of 3.5 kg in 6 months on a small number of patients [159], an evidence which
was later confirmed in a larger study [160].
Topiramate is another drug that has been studied for reducing weight gain where
weight loss has been reported in 10–20% of patients [161], which depended on several fac-
tors such as initial body-mass index (BMI) and duration of the treatment [162]. The anorex-
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igenic capability of topiramate appears to be linked to the reduction of glutamatergic
activity [163] and to changes in the neuropeptide Y expression in the hypothalamus [164].
Another therapeutic strategy aimed at controlling weight gain is histamine H2 receptor
antagonism. Nizatidine, an H2 antagonist used primarily as an anti-ulcer drug, was able to
lower olanzapine-induced body weight and leptin serum levels [165,166].
For AAP-induced dyslipidemia, one pharmacological strategy is the use of statins,
such as simvastatin, lovastatin, atorvastatin and rosuvastatin, as several studies support
their use in schizophrenic patients [1,157,158]. In a recent in vivo study by Liu et al. (2019),
administration of simvastatin concomitantly with olanzapine reduced plasma lipid levels
and liver fat concentrations in rats. Simvastatin resulted in down-regulation of SREBP-
1, FASN (fatty acid synthase), CLY (ATP citrate lyase), ACC (acetyl-CoA-carboxylase),
and SCD-1 (stearoyl-coa-desaturase-1) genes, whose expression is increased after olanza-
pine treatment. Furthermore, the hepatic expression of mTORc1 decreased after treating
with statins. In the liver, mTORc1 is associated with lipid biosynthesis [167] and it can
be overactivated by AAPs [168]. Statins also reduces many inflammatory indices such as
C-reactive protein, interleukin-1β, and tumor necrosis factor-α [169].
Another drug used for weight control is orlistat, a lipase inhibitor, which should
be combined with a reduced fat diet. The advantage of orlistat is that it does not affect
the CNS, but it can however affect the gastrointestinal system causing diarrhea, bloating,
and cramps [160].
Nevertheless, orlistat seems more effective in preventing weight regain than in pro-
moting weight loss [170].
7. Towards a Personalized Therapy: AAPs Plasma Concentration Monitoring
and Pharmacogenetics
Despite APs treatments, more than 1/3 of patients do not benefit from the pharmaco-
logical therapy. Among the factors responsible for the inadequacy of the pharmacologic
treatments, besides using standard dose, suboptimal plasma drug concentration (Cp)
is one of them. In addition, unexpected high Cp can be responsible for severe side effects.
Both these conditions can have a negative impact on patient adherence and compliance to
the treatment. The pharmacokinetic unique characteristics of each individual, especially in
terms of metabolism, and/or drug-drug interactions can be responsible for the unexpected
results mentioned above [171].
For these issues, TDM is an effective tool to improve adherence to pharmacological
treatments in clinical practice by measuring Cp, towards a personalized medicine by
identifying each individual patient’s best therapeutic concentration [172]. For AAPs and
TAPs, the use of TDM is strongly recommended (Level I recommendation) based on the
evidence of a good correlation between Cp, clinical response and the onset of APs-induced
severe side effects [171,172].
Neuroimaging studies have demonstrated that motor-related side effects may occur
when more than 80% of D2 receptors in the striatum are blocked by APs. Importantly, a cor-
relation was found between the D2 receptor occupancy and the Cp of some APs, while such
a relationship with dose was less clear [173]. One reason for such a discrepancy is related
to the APs metabolism that involves different cytochromes such as CYP1A2, CYP2D6,
and CYP3A4 that are known to be genetically polymorphic among the general population.
These analyses have also found that the relationship between Cp and D2 receptor occu-
pancy is fit by a hyperbolic saturation curve, where risperidone and olanzapine, at higher
concentration, may exceed 80% of receptor occupancy [174]. On the contrary, even at high
concentrations clozapine never reaches this level of D2 receptor occupancy. These satura-
tion curves allow predicting D2 receptor occupancy by measuring Cp, a correlation that
is especially valid for olanzapine. For risperidone, the analysis becomes more complex
because the efflux transporter P-glycoprotein (P-gp) may be responsible for lowering its
concentration in the brain, thereby making the relationship between Cp and D2 receptor
occupancy less predictable. Therefore, possible correlation between Cp and other targets
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are also being analyzed, such as the 5-HT2A and GlyT1 transporters; however, the results
are still preliminary [175].
With reference to clozapine, many TDM studies have been carried out mainly due to
its Cp, large variability at standard dose and relevant side effects. Sex, age, smoking and
concomitant use of other medications, such as antiepileptics (e.g., carbamazepine) and SSRI
(e.g., fluvoxamine), may influence clozapine Cp up to ten times. Similar interactions
were also found for other AAPs such as olanzapine and risperidone in association with
carbamazepine or SSRIs [176].
A correlation was found between Cp of clozapine and increased risk of epileptic
seizures; hence the strong suggestion to use TDM during its usage [177]. Moreover,
a fluctuation of Cp during AAPs usage can have a negative effect on relapses and re-
hospitalization in psychotic patients, where TDM might help reduce such a risk. Finally,
higher Cp of AAPs can be associated with an increased risk of metabolic alterations in
schizophrenic patients [178].
Taken together, these data clearly show the utility of TDM in patients undergoing
AAP treatment. However, in order to obtain relevant benefits, TDM should be properly
integrated in the daily clinical practice where a multidisciplinary approach is applied to
take advantage of the expertise of each specialist, i.e., pharmacologists and clinician doctors.
When moving towards a tailored therapy, pharmacogenetics could be relevant for char-
acterizing predictive genetic variants affecting Cp, drug response, and adverse reactions.
Isoforms of CYP enzymes are known to influence the pharmacokinetics of many drugs,
and single nucleotide polymorphisms (SNPs) have been reported for AAPs on CYP2D6,
CYP1A2, CYP3A4, CYP2C9, and CYP2C19 that are responsible for interindividual variabil-
ity in Cp, and to some extent drug efficacy. For instance, the CYP2D6 poor metabolizers
showed higher plasma levels of haloperidol, aripiprazole, risperidone and other com-
monly used APs [179]. The genetic variability of CYP1A2, the main metabolic enzyme for
clozapine and olanzapine, partially explains the variability of their plasma levels [180].
With reference to efficacy, given the importance of dopaminergic and serotoninergic sys-
tems, polymorphisms on the DRD2, DRD3, 5HTR1A, and 5HTR2A receptor genes showed
some influence in AAPs response, although the association was modest [179,181]. A recent
review and meta-analysis on genetic polymorphisms affecting clozapine efficacy [182] re-
ported only three polymorphisms in serotonin receptor genes related to clozapine efficacy,
rs6313 and rs6314 within the HTR2A gene, rs1062613 within the HT3A gene, but no link
with induced weight gain. Serotoninergic genes are also involved in metabolic adverse
reactions, where polymorphisms on 5HTR2A and 5HTR2C were associated to weight gain,
greater waist circumference, increase in BMI and MetS [10,183]. Besides preliminary data,
we believe that currently there is no clear correlation between genetic polymorphisms
and the risk of MetS during AAP use, demonstrating how several factors (genetic and not
genetic) are probably involved for determining this complex phenotype.
8. Conclusions
The use of AAPs in clinical practice as first choice for treating psychotic disorders is
based on their higher efficacy on the cognitive symptoms and reduced motor side effects
compared to TAPs. However, the frequent occurrence of MetS, especially in the terms of
T2D and obesity, with AAPs has seriously questioned their overall superiority over the
other drugs.
It is surprising how these relevant side effects have not been properly considered
in the past, but now finally clinicians are aware of their importance and they are firmly
addressing these issues. The need of a prompt intervention to prevent or reduce AAPs-
induced MetS is mandatory, and treatments based on psychoeducation, physical exercise
and diet have proven to be successful through programs that are feasible and affordable.
When these schemes fail, fortunately, there are several pharmacological options available
to treat MetS, which have been underused in schizophrenic patients so far.
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One should know that the presence of T2D or obesity could negatively affect patient
compliance and lead to drug suspension, resulting in relapse and poor clinical outcomes.
In addition, weight gain increases the social stigma associated with mental illness, and it
often pushes the patients to abandon their treatments.
Olanzapine and clozapine are associated with the greatest risk of MetS; however,
these aspects must be considered together with their higher efficacy, where clozapine still
remains the most effective AAP. The newer AAPs such as ziprasidone, lurasidone are
more tolerable on the metabolic profile, but their overall clinical efficacy is less compared
with clozapine.
We might conclude that there is a correlation between AAP’s clinical efficacy and
likelihood of metabolic alterations, whereas drugs with the highest activity in terms of
number of receptor targets (e.g., clozapine) are the ones with the major risk of MetS.
Indeed, the AAPs-induced MetS is the consequence of a broad activity on the CNS
(mostly the hypothalamus) and peripheral organs, especially by interfering with the activity
of various GPCRs expressed in these tissues. Finally, it is imperative to have a better
understanding of the molecular mechanisms responsible of the clinical differences among
the AAPs in order to find new and better drugs.
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